Exchange: NASDAQ·Updated 07:42 PM EST

BNTX News

News
all
press releases
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages
Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have given a hold...
MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages
Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have given a hold...
MarketBeat
More News
MRNA's ambitious oncology investments and expanding vaccine portfolio drive growth, but rising costs and uncertain revenues test its financial recovery.
Zacks
Large drugmakers and specialized investors continued to favor targeted capability additions, asset purchases, and co-funding arrangements over outright buyouts of late-stage biotechs this week.
Stocktwits
Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.
Zacks
Pfizer beats third-quarter earnings and revenue estimates, driven by strong non-COVID product sales, and increases its 2026 guidance.
Zacks
Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.
Stocktwits
Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
Zacks
Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
Zacks
Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.
Stocktwits
Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.
Zacks

Advertisement|Remove ads.